Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 6/20 | 0.48 |
| ▸ | CA2 | P00918 | 6/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL27705627 | 0.95 | ACHE (0.62) | ACHEALDH1A1TSHRNT5ETEAD4 | |
| SCHEMBL29225799 | 0.92 | ACHE (0.65) | ACHEALDH1A1TSHRNT5ETEAD4 | |
| Sulfamate SCHEMBL28135386 | 0.92 | ACHE (0.65) | ACHEALDH1A1TSHRNT5ETEAD4 | |
| SCHEMBL735335 | 0.86 | ACHE (0.56) | ACHEALDH1A1TSHRNT5ETEAD4 | |
| SCHEMBL11821857 | 0.86 | TSHR (0.78) | ACHEALDH1A1TSHRNT5ETDP1 | |
| SCHEMBL11782818 | 0.86 | TSHR (0.78) | ACHEALDH1A1TSHRNT5ETDP1 | |
| SCHEMBL8421197 | 0.86 | TSHR (0.78) | ACHEALDH1A1TSHRNT5ETDP1 | |
| Sulfuric Acid SCHEMBL28230651 | 0.86 | TSHR (0.62) | ACHEALDH1A1TSHRNT5ETDP1 | |
| P-Xylene SCHEMBL2456088 | 0.86 | GAA (0.58) | ACHEALDH1A1TSHRTDP1POLB | |
| P-Xylene SCHEMBL27791681 | 0.86 | GAA (0.58) | ACHEALDH1A1TSHRTDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136537-A1 | SYSTEM AND PROCESS FOR CONTINUOUS PREPARATION OF meta-CRESOL BY NOx | DEEPAK NITRITE LIMITED (IN) | 2025-05-01 | — | — | US | claimed |
| WO-2023047194-A1 | SYSTEM AND PROCESS FOR CONTINUOUS PREPARATION OF meta-CRESOL BY NOx | DEEPAK NITRITE LIMITED (IN) | 2023-03-30 | — | — | WO | claimed |
| WO-2023047194-A1 | SYSTEM AND PROCESS FOR CONTINUOUS PREPARATION OF meta-CRESOL BY NOx | DEEPAK NITRITE LIMITED (IN) | 2023-03-30 | — | — | WO | disclosed |
| CN-1907253-A | Composition comprising amino heterocyclic compound for hair dyeing and dyeing method | SU JIANHUA (CN) | 2007-02-07 | — | — | CN | disclosed |
| US-20040072775-A1 | Enhancing the sensitivity of tumor cells to therapies | SOBOL ROBERT (US) | 2004-04-15 | — | — | US | disclosed |
| US-20020153251-A1 | Multichannel control in microfluidics | SASSI ALEXANDER (US) | 2002-10-24 | — | — | US | disclosed |
| US-20020010144-A1 | Enhancing the sensitivity of tumor cells to therapies | SOBOL ROBERT (US) | 2002-01-24 | — | — | US | disclosed |
| US-20020006914-A1 | Enhancing the sensitivity of tumor cells to therapies | SOBOL ROBERT E (US) | 2002-01-17 | — | — | US | disclosed |
| EP-1157270-A1 | MULTICHANNEL CONTROL IN MICROFLUIDICS | Aclara BioSciences, Inc. (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000046595-A1 | MULTICHANNEL CONTROL IN MICROFLUIDICS | ACLARA BIOSCIENCES, INC. (US) | 2000-08-10 | — | — | WO | disclosed |
| US-5871923-A | Methods for screening for antimycotics | RIBOGENE, INC. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5641627-A | MEASURING EXPRESSION LEVEL OF REPORTER GENE WHEN MYCOTIC CELLS ARE TREATED WITH POTENTIAL TRANSLATION(GENETIC) INHIBITORS | RIBOGENE, INC. (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0769146-A2 | SCREENING FOR NUC INHIBITORS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-04-23 | — | — | EP | disclosed |
| EP-0765475-A1 | SCREENING FOR CYTOKINE MODULATORS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-04-02 | — | — | EP | disclosed |
| EP-0758382-A1 | ENHANCING THE SENSITIVITY OF TUMOR CELLS TO THERAPIES | SIDNEY KIMMEL CANCER CENTER (US) | 1997-02-19 | — | — | EP | disclosed |
| EP-0725818-A1 | METHODS FOR SCREENING FOR ANTIMYCOTICS | Ribogene, Inc. (US) | 1996-08-14 | — | — | EP | disclosed |
| WO-1996001430-A2 | SCREENING FOR NUC INHIBITORS | LIGAND PHARMACEUTICALS, INCORPORATED (US) | 1996-01-18 | — | — | WO | disclosed |
| WO-1995031722-A1 | SCREENING FOR CYTOKINE MODULATORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-11-23 | — | — | WO | disclosed |
| WO-1995030002-A2 | ENHANCING THE SENSITIVITY OF TUMOR CELLS TO THERAPIES | SAN DIEGO REGIONAL CANCER CENTER (US) | 1995-11-09 | — | — | WO | disclosed |
| WO-1995011969-A1 | METHODS FOR SCREENING FOR ANTIMYCOTICS | RIBOGENE, INC. (US) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136537-A1 | SYSTEM AND PROCESS FOR CONTINUOUS PREPARATION OF meta-CRESOL BY NOx | NOX1, NOX5, NOXO1 | ACHE 263/4885ALDH1A1 3732/4885TSHR 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.